Skip to main content

Zimmer Biomet Holdings(ZBH-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low92.59
Day High95.89
Open:95.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
QSM Asset Management Loads Up 611,000 Mobileye Shares
Tipranks
RBC Capital Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH)
Motley Fool
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound?
Motley Fool
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zimmer Biomet Holdings (ZBH) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
StockStory
3 Cash-Producing Stocks We Keep Off Our Radar
NKE
Zacks Investment Research
Can 13-15% Procedure Growth in 2026 Sustain ISRG's Premium Valuation?
Can 13-15% Procedure Growth in 2026 Sustain ISRG's Premium Valuation?
Tipranks
Citi Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)
StockStory
3 Value Stocks We Find Risky
ZBH
Tipranks
Zimmer Biomet’s RibFix Titan Study: What Chest Wall Data Could Mean for ZBH Investors
Tipranks
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX)
Tipranks
Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement
Motley Fool
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
StockStory
Surgical Equipment & Consumables - Diversified Stocks Q4 In Review: Zimmer Biomet (NYSE:ZBH) Vs Peers
ZBH
Zacks Investment Research
ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead?
ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead?
Tipranks
Citi Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)
StockStory
3 Healthcare Stocks We Think Twice About
STE
Tipranks
Stifel Nicolaus Remains a Buy on Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Taysha Gene Therapies (TSHA) and Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth
Tipranks
BTIG Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction
StockStory
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
ZBH
StockStory
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
ZBH
StockStory
The Top 5 Analyst Questions From Zimmer Biomet’s Q4 Earnings Call
ZBH
Tipranks
Barclays Sticks to Their Sell Rating for Zimmer Biomet Holdings (ZBH)
MarketBeat
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
MarketBeat.com
Tipranks
RBC Capital Remains a Buy on Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet Holdings (ZBH) Receives a Hold from Canaccord Genuity
Tipranks
Wells Fargo Keeps Their Hold Rating on Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (EXEL), Edwards Lifesciences (EW) and Zimmer Biomet Holdings (ZBH)

Profile

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.